Sun Pharma has reported a 49% growth in net profits in the third quarter of the current year on the back of a 41% growth in the topline. Formulations, which account for 66% of the company’s turnover grew by 39% in the third quarter while bulk drugs grew by 43%. Sun Pharmaceuticals manufactures formulations in niche segments such as psychiatry, cardiovascular, gastroentology and neurology.
The company has also managed to improve its margins in the third quarter by 190 basis points despite the fact that Gujarat Lyka (which produces bulk drugs) has been amalgamated with Sun Pharma in the current year.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
Earnings per share*
What is encouraging for the company is the continuous growth in formulation exports, which have almost quadrupled in the third quarter. A primary reason for the stupendous growth is the amalgamation of Sun Pharmaceutical Exports during the quarter.
Also, Sun has been extremely aggressive in the launch of new products in the domestic market with 24 new product launches in the first nine months of the current year which has helped it maintain its dominance in the cardiovascular, diabetes and central nervous system.
Perhaps the only area of concern is the continuing losses of its US based affiliate Caraco Pharma, which is the company’s vehicle for launch of generics. (Sun has invested Rs 288.63 m towards equity and Rs 252.86 m towards debt in Caraco, which is expected to register a loss of around $ 6 m for the year ended December 2000, although it has not announced the same.) Caraco has submitted around nine abbreviated new drug applications (ANDA) which are awaiting US FDA approval and only after their approvals can revenues start to flow in. Sun has however not provided for this diminution in the value of its investments in its books.
The stock quotes at Rs 560 which implies an earnings multiple of 19.2 times FY01 annualised earnings.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407